US equities
|
MU
$836.43
▼-5.46%
NVDA
$203.97
▼-0.33%
TSLA
$404.45
▲+1.16%
AAPL
$337.47
▼-2.08%
AMD
$474.14
▼-6.07%
INTC
$60.30
▼-8.30%
MSFT
$514.21
▼-1.48%
AMZN
$248.28
▲+3.30%
MU
$836.43
▼-5.46%
NVDA
$203.97
▼-0.33%
TSLA
$404.45
▲+1.16%
AAPL
$337.47
▼-2.08%
AMD
$474.14
▼-6.07%
INTC
$60.30
▼-8.30%
MSFT
$514.21
▼-1.48%
AMZN
$248.28
▲+3.30%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by BPGbio
BPGbio Publishes Pioneering Research on Novel Brain-Penetrant Therapeutic Candidate for Glioma
October 28, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients
October 26, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Appoints Jason Krause as Senior Vice President and General Counsel
October 22, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Reports Encouraging Preliminary Data from Ongoing Phase 2 Study of BPM31510 in Newly Diagnosed Glioblastoma
July 15, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Presents Latest Clinical and Translational Findings Supporting BPM31510 in Primary CoQ10 Deficiency at Mito Med 2026
June 17, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board
June 09, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026
May 28, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Appoints Former Oxford Pro-Vice Chancellor for Innovation Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer
April 21, 2026
From
BPGbio
Via
GlobeNewswire
Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging
February 02, 2026
From
BPGbio
Via
GlobeNewswire
UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
January 21, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
January 20, 2026
From
BPGbio
Via
GlobeNewswire
BPGbio Announces Publication of Pioneering Solid Tumor Study with BPM31510 IV using Patient Omics and Bayesian AI to Guide Clinical Development
December 16, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Appoints John Dvor as Executive Vice President, Corporate Development
November 11, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Wins 2025 AI Drug Development Innovation Award from Biotech Breakthrough Awards
November 06, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025
October 16, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
October 20, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Welcomes Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in Residence
October 14, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Appoints Veteran Clinical and Commercial Leader Dr. Brian Berman as Interim Chief Medical Officer
October 06, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
September 24, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief AI Officer
September 23, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)
September 04, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025
May 28, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency
June 18, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio CEO Dr. Niven R. Narain Named to The Medicine Maker Power List 2025
April 28, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference
April 25, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio Presents New Research on Tumor Metabolism, Immunotherapy, and Diagnostics at AACR Annual Meeting 2025
April 23, 2025
From
BPGbio
Via
GlobeNewswire
BPGbio's Lipidomics Expertise Powers Groundbreaking Discovery of Lipid-Rich Cartilage Published in Science
January 09, 2025
From
BPGbio
Via
Business Wire
BPGbio Announces Publication in Scientific Reports on Validation of Novel Diagnostic Biomarker Panel for Parkinson’s Disease
May 20, 2024
From
BPGbio
Via
Business Wire
